Soft tissue regeneration company Aroa Biosurgery has seen its share price lift, after updating revenue guidance for its 2023 financial year to $62 million to $64m.
The guidance includes $2m of project and licence fees, and follows strong US sales and favourable exchange rate tailwinds.
In trading
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
